These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31905966)

  • 101. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
    García-Teijido P; Cabal ML; Fernández IP; Pérez YF
    Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
    Stovgaard ES; Nielsen D; Hogdall E; Balslev E
    Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
    Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905966
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
    Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
    Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 107. FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer.
    Shiau JP; Wu CC; Chang SJ; Pan MR; Liu W; Ou-Yang F; Chen FM; Hou MF; Shih SL; Luo CW
    Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944605
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
    Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
    Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients.
    Zhang Y; Wang S; Yang B; Lu S; Du Y; Liu H
    Cancer Biol Med; 2019 May; 16(2):350-360. PubMed ID: 31516755
    [TBL] [Abstract][Full Text] [Related]  

  • 110. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
    Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
    J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
    Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
    Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
    [TBL] [Abstract][Full Text] [Related]  

  • 113. FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer.
    Pan MR; Hou MF; Ou-Yang F; Wu CC; Chang SJ; Hung WC; Yip HK; Luo CW
    J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30609732
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O
    Hsu SH; Chen SH; Kuo CC; Chang JY
    Biochem Pharmacol; 2018 Dec; 158():327-338. PubMed ID: 30449727
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Chan SH; Tsai KW; Chiu SY; Kuo WH; Chen HY; Jiang SS; Chang KJ; Hung WC; Wang LH
    Mol Cancer Ther; 2019 Jan; 18(1):147-161. PubMed ID: 30381446
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer.
    Tiede S; Meyer-Schaller N; Kalathur RKR; Ivanek R; Fagiani E; Schmassmann P; Stillhard P; Häfliger S; Kraut N; Schweifer N; Waizenegger IC; Bill R; Christofori G
    Oncogenesis; 2018 Sep; 7(9):73. PubMed ID: 30237500
    [TBL] [Abstract][Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.